Company: SRPT
Filing Date: 2025-02-28
Form Type: 10-K
Source: 0000950170-25-029973
Chunk: 293

Company: Sarepta Therapeutics, Inc.
Filing Date: 2025-02-28
Form: 10-K
Item: Item 1
Chunk 293
---
    2,002,112

    1,868,482

    923,224

    Purchase of intangible assets

    (10,000
    )

    (11,239
    )

    (1,427
    )

    Acquisition of strategic investments

    —

    (4,000
    )

    (1,000
    )

    Proceeds from sale of Priority Review Voucher

    —

    102,000

    —

    Net cash provided by (used in) investing activities

    755,561

    (165,803
    )

    (1,046,883
    )

    Cash flows from financing activities:

    Settlement of capped call share options for 2024 Notes

    45,349

    80,645

    26,317

    Proceeds from exercise of stock options and purchase of stock under the     Employee Stock Purchase Program

    79,525

    51,246

    30,043

    Payment on maturity of 2024 Notes

    (68
    )

    —

    —

    Debt conversion costs for 2024 Notes

    —

    (6,887
    )

    —

    Proceeds from 2027 Notes offering, net of commissions

    —

    —

    1,127,400

    Purchase of capped call share options for 2027 Notes

    —

    —

    (127,305
    )

    Debt issuance costs for 2027 Notes

    —

    —

    (716
    )

    Repurchase of 2024 Notes

    —

    —

    (247,868
    )

    Repayment of principal amount due under 2019 Term Loan

    —

    —

    (550,000
    )

    Payment on debt extinguishment of 2019 Term Loan

    —

    —

    (25,364
    )

    Net cash provided by financing activities

    124,806

    125,004

    232,507

    Increase (decrease) in cash and cash equivalents

    674,580

    (541,792
    )

    (1,139,722
    )

    Cash, cash equivalents and restricted cash:

    Beginning of year

    444,009

    985,801

    2,125,523

    End of year
     
    $
    1,118,589

    $